Home » APPROVAL BLOG
Durvalumab receives FDA-approval as a consolidation treatment for Stage III NSCLC
On February 16, 2018 the FDA approved Imfinzi® (durvalumab) as a consolidation treatment for patients with stage III non-small cell…
Read More